Delta Asia International (6762) reported revenue of NT$53.8 million for Oct 2026, -2.0% year on year and -21.3% from the previous month. Revenue for Jan–Oct 2026 was NT$627.2 million (+6.5% year on year).
In Oct 2026, it ranked No. 95 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$53.8 million | -2.0% | -21.3% |
| Sep 2026 | NT$68.3 million | +26.5% | -16.1% |
| Aug 2026 | NT$81.5 million | +35.5% | +0.7% |
| Jul 2026 | NT$80.9 million | +31.8% | +5.9% |
| Jun 2026 | NT$76.4 million | +21.8% | +8.4% |
| May 2026 | NT$70.5 million | +13.0% | +17.1% |
| Apr 2026 | NT$60.2 million | -14.2% | +15.6% |
| Mar 2026 | NT$52 million | -14.9% | +60.2% |
| Feb 2026 | NT$32.5 million | -36.4% | -36.7% |
| Jan 2026 | NT$51.3 million | -0.4% | +1.8% |
| Dec 2025 | NT$50.4 million | -18.5% | -7.8% |
| Nov 2025 | NT$54.6 million | -11.3% | -0.4% |
| Oct 2025 | NT$54.9 million | +2.5% | +1.6% |
| Sep 2025 | NT$54 million | -4.5% | -10.2% |
| Aug 2025 | NT$60.1 million | +3.1% | -2.0% |
| Jul 2025 | NT$61.4 million | +21.0% | -2.1% |
| Jun 2025 | NT$62.7 million | +34.0% | +0.6% |
| May 2025 | NT$62.3 million | +22.7% | -11.0% |
| Apr 2025 | NT$70.1 million | +75.0% | +14.7% |
| Mar 2025 | NT$61.1 million | +104.0% | +19.7% |
| Feb 2025 | NT$51 million | +41.9% | -0.9% |
| Jan 2025 | NT$51.5 million | +49.8% | -16.7% |
| Dec 2024 | NT$61.8 million | +101.4% | +0.4% |
| Nov 2024 | NT$61.6 million | +98.4% | +15.0% |
| Oct 2024 | NT$53.5 million | +22.2% | -5.4% |
Jan–Oct 2026 cumulative: NT$627.2 million (+6.5% YoY)
Other Biotech & Medical companies
Compare with peers: Delta Asia International vs PEC / Delta Asia International vs Lotus Pharm / Delta Asia International vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16